Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Intra peritoneal (IP) therapy for high-grade ovarian cancer seemed a good idea. Metastasis to the peritoneum occurs early, direct treatment was thought to improve outcomes.
However, the reality is that IP therapy is intrusive and painful, with high complication rates and toxicity. A randomised trial compared intravenous (IV) chemo alone with two groups, both receiving the same IV therapy as the control; and in addition, one IP chemo weekly and the other IP chemo every 3 weeks.
No benefit, measured as increased progression free survival, was recorded in any of the 3 groups. The quality of life, as measured by functional assessment (FACT-O), was significantly worse in those receiving IP therapy.
No comments:
Post a Comment